



INVESTORS' CORPORATE FACT SHEET

Contact: Spencer Sias (650) 424-5782
Vice President of Corporate Communications &
Investor Relations
Varian Medical Systems, Inc.

* All data as of July 1, 2005

NYSE Symbol: VAR	Stock Price : \$37.00	<u>Company Officers</u>
Market Capitalization: \$4.9 billion	52-Week Range: \$26.63 – \$43.99 ²	Richard M. Levy, President/CEO
Basic Shares Outstanding: 131 mm	Avg. Daily Volume: 1,108,298 (3 mo.)	Timothy E. Guertin, EVP/COO
Institutional Ownership¹:	Q305 Revenues/EPS: \$347 mm / \$0.37	Elisha W. Finney, SVP/CFO
305 institutions / 84.3%	Employees: 3,508	Robert H. Kluge, VP/X-Ray Products
Management Ownership: 6.2%	Fiscal Year Ends: 9/30/05	John W. Kuo, VP, General Counsel
		Dow R. Wilson, VP/Oncology Systems
		George Zdasiuk, VP/CTO

Largest Institutional Owners¹

Putnam Investment Mgmt, LLC
Artisan Partners LP
Franklin Advisers, Inc.
OppenheimerFunds, Inc.
Barclays Global Investors, N.A.

American Century Investment Mgmt.
Mazama Capital Mgmt., Inc.
State Street Global Advisors (US)
Neuberger Berman, LLC
Merrill Lynch Investment Mgrs (NJ)

Financial Analyst Coverage

Amit Hazan, SunTrust Robinson Humphrey
Julie Hoggatt, Variant Research Corp.³
Tycho Peterson, JP Morgan Securities
Ryan Rauch, Jefferies & Company
Randy Scherago, First Albany Capital
Kate Sharadin, Pacific Growth Equities
Richard Yett, Monness, Crespi & Hardt

¹ Source: 07/01/05 Thomson Financial

² Adjusted to reflect July 30, 2004 two-for-one stock split

³ Initiated coverage July 21, 2005

Company Background

Varian Medical Systems, Inc., (NYSE: VAR) serves the medical equipment market as the world's leading manufacturer of integrated radiotherapy systems for treating cancer and the premier supplier of X-ray tubes and flat panels for diagnostic imaging applications. Business units include:

Oncology Systems:

- This unit is the world's largest supplier of radiotherapy systems for treating cancer. Its integrated medical systems include sales and service of linear accelerators, and ancillary products for treatment planning, quality assurance, image processing, record management, and clinical administration. Thousands of patients around the world are treated daily on Varian systems. Oncology Systems works closely with healthcare professionals in clinics, hospitals, and universities worldwide, addressing their requirements for continually improving treatment efficacy and cost containment.

X-Ray Products:

- This business unit is the world's premier independent supplier of X-ray generating tubes. It serves major original equipment manufacturers in the diagnostic imaging industry and replacement tube distributors. The business provides the industry's broadest selection of X-ray tubes expressly designed for the most advanced CT scanning, radiographic, mammographic, and other diagnostic applications. These products are continuously evolving to meet more and more stringent requirements for high-resolution imaging, rapid examination, patient throughput, long tube life, and cost efficiency. X-Ray Products also manages an emerging business in flat panel x-ray image detectors using amorphous silicon technology.

Other:

- The Company's third business segment combines the Ginzton Technology Center (GTC) and the BrachyTherapy group. The GTC acts as the company's research and development facility for breakthrough technologies. Current Ginzton efforts are focused on imaging as well as emerging technologies that shrink tumors by triggering therapeutic gene activity with radiation beams. This unit also conducts externally funded contract research related to medical technology, which may lead to long-term partnerships and new business opportunities. The BrachyTherapy unit supplies afterloaders, accessories and treatment planning software for placement of radiation sources within cancerous tumor sites.

Varian Medical Systems Financial Overview

Consolidated Statements of Earnings

(Dollars in millions, except per share amounts)	Fiscal Year Ended			Third Quarter Ended (Unaudited)		
	Oct. 1, 2004 (As Adjusted) ⁽¹⁾	Sept. 26, 2003 (As Adjusted) ⁽¹⁾	%Growth	Jul. 1, 2005	Jul. 2, 2004 (As Adjusted) ⁽¹⁾	%Growth
Revenues:						
Oncology Systems	\$ 1,030.5	\$ 855.6	20%	\$285.8	\$252.2	13%
X-Ray Products	165.4	152.9	8%	49.2	41.3	20%
Ginzton Technology Center	39.6	33.1	20%	11.6	9.6	20%
Total Revenues	1,235.5	1,041.6	19%	346.6	303.1	14%
Operating costs and expenses:						
Cost of revenues	717.3	620.5		194.7	172.1	
Research and development	72.1	59.2		21.9	17.7	
Selling, general and administrative	189.4	164.3		54.7	47.7	
Total operating costs & expenses	978.8	844.0		271.3	237.5	
Operating earnings	256.7	197.6		75.3	65.6	
Interest income, net	(1.3)	(3.0)		(1.1)	(0.2)	
Earnings before taxes	258.0	200.6		76.4	65.8	
Taxes on earnings	90.3	70.2		25.3	23.1	
Net earnings	\$ 167.7	\$ 130.4	29%	\$ 51.1	\$42.7	20%
Diluted EPS ⁽²⁾	\$ 1.18	\$ 0.92	28%	\$ 0.37	\$ 0.30	23%

⁽¹⁾ Certain amounts have been adjusted to reflect the Company's change from the LIFO method to the FIFO method of accounting for inventories in the third quarter of fiscal year 2004. This change had no impact on the basic or diluted EPS for any of the periods presented.

⁽²⁾ Diluted EPS for the fiscal year ended September 26, 2003 has been adjusted for the two-for-one stock split (effected in the form of a 100 percent stock dividend) paid on July 30, 2004.


Key Balance Sheet Data

(Dollars in thousands)	Jul. 1, 2005	Oct. 1, 2004
Working capital	\$ 411,556	\$ 434,245
Total assets	\$1,246,559	\$1,180,640
Stockholders' equity	\$ 631,666	\$ 624,162


Revenue by Region (FY2004)

North America 56%
Rest of World 44%


Revenues




Operating Costs and Expenses



Earnings Before Taxes



Net Earnings



Investor Relations Contacts:

Elisha W. Finney, Senior Vice President, CFO 650.424.6803(p) elisha.finney@varian.com
Spencer R. Sias, Vice President, Investor Relations 650.424.5782 (p) spencer.sias@varian.com

Note: This document contains summary financial information. Please refer to Varian's Form 10-K, Form 10-Q, and financial press releases for more detailed financial information. Except for information packet requests, the Company does not respond to investor inquiries submitted via e-mail.